Please login to the form below

Not currently logged in
Email:
Password:

Inclisiran

This page shows the latest Inclisiran news and features for those working in and with pharma, biotech and healthcare.

Novartis scores CHMP backing for cholesterol drug Leqvio

Novartis scores CHMP backing for cholesterol drug Leqvio

Leqvio ( inclisiran) is a potential first-in-class treatment for high cholesterol in Europe for patients with hypercholesterolemia or mixed dyslipidemia.

Latest news

More from news
Approximately 9 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    8. Inclisiran from The Medicines Company (now a Novartis wholly owned subsidiary) is being reviewed for approval in hypercholesterolemia in the US and the EU. ... Inclisiran must leverage its strong efficacy and twice-a-year dosing to succeed.

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    Meanwhile, there’s considerable excitement about Novartis-partnered cholesterol-lowering therapy inclisiran, which is also up for an FDA decision this year and has been tipped to become a mega-blockbuster

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    Alnylam has three more RNAi medicines in its late stage pipeline: Fitusiran in haemophilia, being co-developed with Sanofi; inclisiran for hypercholesterolemia being co-developed by the Medicines Company; and lumisiran

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics